clinical trial failure

Valneva stock plummets 37% after Phase 3 Lyme vaccine candidate fails trial; law firm investigates potential securities fraud claims.

Mereo BioPharma faces class action lawsuit alleging misrepresentations regarding failed Phase 3 clinical trials, with lead plaintiff deadline April 6, 2026.

Rosen Law Firm urges MREO investors to act before April 6, 2026 deadline in securities class action alleging misleading clinical trial statements.

Nektar Therapeutics faces class action lawsuit over alleged failure to disclose enrollment protocol violations in failed Phase 2b REZOLVE-AA trial, triggering 8% stock decline.

Portnoy Law Firm investigates Novo Nordisk for possible securities fraud after CagriSema obesity drug failed trial, triggering 16.43% stock decline.

Rhythm Pharmaceuticals' setmelanotide fails EMANATE Phase 3 primary endpoints for rare genetic obesity, sending stock down 4.98%. Company pivots to next-generation MC4R agonists.

Rosen Law Firm urges MREO investors to join class action over alleged misleading statements regarding setrusumab Phase 3 trial failures.

Class action lawsuit filed against Mereo BioPharma over alleged misstatements regarding failed Phase 3 clinical trials. Investors have until April 6, 2026, to join.

Law firm investigates $NKTR over December trial failure disclosure. Stock dropped 7.8% after alopecia areata Phase 2b study missed endpoints due to ineligible patients.

Ultragenyx Pharmaceutical's stock plunged 42% after failing to disclose setrusumab Phase 3 trial failure, triggering securities litigation with April 6, 2026 lead plaintiff deadline.

Nektar Therapeutics faces securities class action over alleged misstatements about REZOLVE-AA trial, with stock falling 7.77% after trial failure announcement.

Pomerantz LLP investigates Gossamer Bio after seralutinib Phase 3 trial failure triggers 80% stock crash, raising securities fraud concerns.

Pomerantz Law Firm filed class action against $MREO after Phase 3 trial failures. Stock plummeted 87.7%. Investor deadline: April 6, 2026.

Mereo BioPharma faces class action over failed Phase 3 trials and alleged misleading statements. Investor deadline April 6, 2026.

Roche's giredestrant failed to meet primary endpoint in Phase 3 breast cancer trial, causing 5% stock decline. Company plans adjuvant trial readout in 2027.

Class action suits filed against Ultragenyx and Mereo BioPharma following failed Phase III trials for setrusumab, with stock prices crashing 42.32% and 87.7% respectively.

Investors in $MREO have until April 6, 2026 to join securities class action alleging misleading statements about failed Phase 3 setrusumab trials.

Ultragenyx Pharmaceutical faces securities fraud lawsuit after setrusumab trials failed. Stock crashed 42% in December; investors have until April 6, 2026, to join action.

Class action filed against Mereo BioPharma over allegedly false statements regarding failed Phase 3 clinical trials, covering $MREO investors from June 2023 to December 2025.

Ultragenyx Pharmaceutical faces securities lawsuit after setrusumab trial failure caused 42% stock decline. Lead plaintiff deadline April 6, 2026.